Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apomorphine subcutaneous - Britannia Pharmaceuticals

Next Previous
Drug Profile

Apomorphine subcutaneous - Britannia Pharmaceuticals

Alternative Names: APO-go; Apokinon; Apokyn; Apomine; Britaject; KW-6500; Li Ke Ji; MOVAPO®; ONAPGOTM; SPN-830

Latest Information Update: 10 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Britannia Pharmaceuticals
  • Developer Britannia Pharmaceuticals; Kyowa Kirin; STADA Arzneimittel; Supernus Pharmaceuticals; US WorldMeds
  • Class Analgesics; Antiparkinsonians; Aporphines; Catechols; Erectile dysfunction therapies; Heterocyclic compounds; Phenanthrenes; Piperidines; Quinolines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Dopamine D2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Parkinson's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease

Most Recent Events

  • 25 Feb 2025 Supernus Pharmaceuticals plans to launch apomorphine infusion pump (SPN 830) for Parkinson's disease in USA in the second quarter of 2025
  • 04 Feb 2025 Registered for Parkinson's disease in USA (SC)
  • 06 Aug 2024 Supernus Pharmaceuticals resubmitts New Drug Application for apomorphine infusion device (SPN-830) for the continuous treatment of motor fluctuations in Parkinson’s disease

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top